Over the past five decades, la cirrosis hepática se ha convertido en una enfermedad cada vez más frecuente y que a menudo requerirá una intervención médica considerable. Sin embargo, current treatment options have demonstrated severe problems that have prompted research to provide a suitable alternative. These treatments are scarcely available, very expensive and present at a huge cost to the patient’s quality of life. The introduction of terapia con células madre into liver disease has been heralded as the future of personalized medicine and may be the alternative that the healthcare system desperately seeks.

To truly determine the scientific basis surrounding this excitement, a literature search was carried out in January 2013 to determine all the data that was present in this topic area. All articles also underwent full cross-referencing to ensure no data was missed.

11 clinical trials were found to meet this criteria and trials were included in both English and non-English languages. The sporadic nature of the data across the trials, with various methods and stem cell types, made comparisons difficult.

The basic trends from the data were positive and the majority deemed the use of stem cells safe and feasible in patients presenting with cirrhotic liver disease. Sin embargo, there is a clear requirement for more research, not only to determine the most efficacious technique and stem cell type but also to further understand stem cells to enhance progress. There may also be a requirement for a framework that future stem cell trials can be based on, which would allow future data to be comparative and allow valid conclusions to be drawn which may propel this therapy into standard clinical practice.

Palabras clave: liver cirrhosis, terapia con células madre, haematopoetic stem cells, células madre mesenquimales, hepatic progenitor cells
Abbreviations: HSC, Hematopoietic stem cell; MSC, Mesenchymal Stem cell; hHPC, Human Hepatic Progenitor cell; Una vez que la cirrosis hepática ha alcanzado la etapa de descompensación, Mononuclear Stem cell; G-CSF, Granulocyte colony stimulating factor


organización de contratos de investigación

terapia con células madre